Edgar Filing: Conatus Pharmaceuticals Inc. - Form 4

Conatus Ph Form 4 June 24, 20	armaceuticals Inc.									
	ЛЛ						-	PPROVAL		
FORM 4 UNITED STATES			SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549				N OMB Number:	3235-0287		
Check t if no lot subject Section Form 4 Form 5 obligati may co	nger to 16. or Filed pur ons ntinue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						January 31, 2005 Estimated average burden hours per response 0.5		
<i>See</i> Inst 1(b).	ruction	50(11) 01 0		. compu	ly 1 101 01 1					
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Klassen Preston			2. Issuer Name and Ticker or Trading Symbol Conatus Pharmaceuticals Inc. [CNAT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	. , .	(Mo 06/ C., 16745	Pate of Earliest T onth/Day/Year) 23/2016	ransaction		_X_ Director Officer (gi below)		% Owner her (specify		
	(Street)		Amendment, D d(Month/Day/Yea	-	1	Applicable Line) _X_ Form filed b	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
SAN DIEC	GO, CA 92127					Person	whole than one R	aporting		
(City)	(State)	(Zip)	Table I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Ye	Code	4. Securit nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each class of	f securities bene	ficially own	ned directly	or indirectly.				
				Perso inform requir	ns who rest nation cont ed to resp	spond to the colle tained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount of 8 Underlying Securities 1 (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 2.13	06/23/2016		А	20,000	<u>(1)</u>	06/22/2026	Common Stock	20,000
Reporting Owners									

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Klassen Preston C/O CONATUS PHARMACEUTICALS INC. 16745 WEST BERNARDO DRIVE, SUITE 200 SAN DIEGO, CA 92127	Х				
Signatures					

Signatur

/s/ Charles J. Cashion, Attorney-in-Fact for Preston S. Klassen

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully

vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of (1) directors of the Issuer through such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: Conatus Pharmaceuticals Inc. - Form 4

Date

06/24/2016